Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
155
CIMA_AEMPS:78
NMPA:60
SFDA:9
+1 more agencies
Drug Approvals
Citrus Bioflavonoids Tablets
- Product Name
- 爱脉朗
- Approval Number
- 国药准字HJ20140455
- Approval Date
- Oct 25, 2024
NMPA
Perindopril Arginine Tablets
- Product Name
- 雅施达
- Approval Number
- 国药准字HJ20140801
- Approval Date
- Sep 3, 2024
NMPA
Perindopril Arginine Tablets
- Product Name
- 雅施达
- Approval Number
- 国药准字HJ20140800
- Approval Date
- Sep 3, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150218
- Approval Date
- May 31, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150273
- Approval Date
- May 31, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150217
- Approval Date
- May 31, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150275
- Approval Date
- May 31, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150274
- Approval Date
- May 31, 2024
NMPA
Ivabradine Hydrochloride Tablets
- Product Name
- 可兰特
- Approval Number
- 国药准字HJ20150272
- Approval Date
- May 31, 2024
NMPA
Gliclazide Modified Release Tablets
- Product Name
- 格列齐特缓释片
- Approval Number
- 国药准字HJ20150283
- Approval Date
- Mar 20, 2024
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
No trials found
News
Liraglutide Shows Promise in Pediatric Obesity, While Oncology Trials Face Setbacks
• Novo Nordisk's liraglutide demonstrated a significant reduction in BMI in a Phase III trial involving children aged 6-11, showing potential for pediatric obesity treatment. • Vaxcyte's VAX-31 pneumonia vaccine showed positive Phase I/II topline data, increasing its Phase Transition Success Rate (PTSR) in streptococcal pneumonia. • Pfizer terminated a Phase I trial of maplirpacept, leading to a decrease in its PTSR for peripheral T cell lymphoma and B cell Hodgkin lymphoma. • Les Laboratoires Servier's oncology drug trial was terminated due to business reasons, impacting the PTSR of S-64315 and S-65487 in multiple myeloma and leukemia.